Indication intelligence, analysis and sector perception

Biostage (BSTG) hires CSO

July 21, 2016 9:35am

To advance pre-clinical studies ...

Harout DerSimonian, Ph.D. has joined BSTG as Chief Scientific Officer (CSO), a new position at Biostage. Dr. DerSimonian will direct and manage the cell biology, materials science and other scientific research that forms the basis of Biostage's Cellframe™ technology platform.

Dr. DerSimonian has over 20 years of experience in developing immunotherapy and cell therapy programs and was instrumental in directing the science that enabled the first FDA-approved clinical trial using autologous human stem cells for cardiac repair. Throughout his career, he has played a critical, senior role in designing and implementing therapeutic programs at leading global institutions. Dr. DerSimonian is a former assistant professor and post-doctoral fellow at Harvard Medical School and completed his post-doctoral training at the Dana-Faber Cancer Institute and Brigham and Women's Hospital. Dr. DerSimonian holds a Ph.D. in immunology from Tufts University and a B.A. in biology from Hartwick College.

The Bottom Line: Cellspan implants are currently being advanced and tested in preclinical studies.

This testing is intended to expand the base of pre-clinical data in support of Biostage's goal of filing an Investigational New Drug (IND) application with the U.S. FDA in late 2016.
The IND will seek approval to initiate clinical trials for its esophageal implants in humans.
An IND filing is NOT a “Holy Grail” …

BSTG closed at $1.11 and is DOWN at the open

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.